Trial Profile

A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologically-suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain With an INI + TAF/FTC ARV Regimen

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir alafenamide; Integrase inhibitors
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms DEFINE

06 Mar 2024 Results presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
13 Sep 2023 Status changed from active, no longer recruiting to completed.
11 Aug 2023 Planned End Date changed from 31 Oct 2023 to 11 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com